ImmuPharma plc, a pharmaceutical company, develops drug candidates based on peptide therapeutics to treat serious medical conditions. The company's lead product candidate is the Lupuzor, which has completed Phase III clinical trial for the treatment of lupus, an autoimmune chronic inflammatory disease. Its other product candidate includes IPP-204106, a peptide to modulate angiogenesis with application in cancer and ophthalmology.
Read More…
Industry, Sector and Symbol
Industry Biotechnology
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone+44-20-71524080
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales£19,626.00
Profitability
Miscellaneous
Employees10
Next Earnings DateN/A
OptionableNot Optionable
ImmuPharma (LON:IMM) Frequently Asked Questions
What is ImmuPharma's stock symbol?
ImmuPharma trades on the London Stock Exchange (LON) under the ticker symbol "IMM."
Has ImmuPharma been receiving favorable news coverage?
Media headlines about IMM stock have been trending very negative recently, InfoTrie reports. The research firm ranks the sentiment of media coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. ImmuPharma earned a news sentiment score of -3.2 on InfoTrie's scale. They also assigned headlines about the company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an impact on the stock's share price in the immediate future. View News Stories for ImmuPharma.
Who are some of ImmuPharma's key competitors?
Some companies that are related to ImmuPharma include Zelda Therapeutics (ZLD), Noxopharm (NOX), Covalon Technologies (COV), AquaBounty Technologies (AQB), Verona Pharma (VRP), Protalix Biotherapeutics (PLX), Medicenna Therapeutics (MDNA), Actinogen Medical (ACW), ReNeuron Group (RENE), Biotron (BIT), Immunoprecise Antibodies (IPA), Exopharm (EX1), Acrux (ACR), Armata Pharmaceuticals (ARMP) and Oncolytics Biotech (ONC).
What other stocks do shareholders of ImmuPharma own?
Who are ImmuPharma's key executives?
ImmuPharma's management team includes the folowing people:
- Mr. Dimitri F. Dimitriou, Co-Founder, CEO & Director (Age 57)
- Dr. D. Robert Henri Zimmer M.D., Ph.D., Co-Founder, Pres, Chief Scientific Officer & Director (Age 71)
- Ms. Tracy Weimar BA, MBA, VP of Operations & Fin. and Company Sec.
- Dr. Jean-Marie Geiger PharmD, MD, Head of Clinical Devel.
How do I buy shares of ImmuPharma?
Shares of IMM and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
What is ImmuPharma's stock price today?
One share of IMM stock can currently be purchased for approximately GBX 7.50.
How big of a company is ImmuPharma?
What is ImmuPharma's official website?
How can I contact ImmuPharma?
ImmuPharma's mailing address is 50 Broadway, LONDON, SW1H 0BL, United Kingdom. The company can be reached via phone at +44-20-71524080.
MarketBeat Community Rating for ImmuPharma (LON IMM)
MarketBeat's community ratings are surveys of what our community members think about ImmuPharma and other stocks. Vote "Outperform" if you believe IMM will outperform the S&P 500 over the long term. Vote "Underperform" if you believe IMM will underperform the S&P 500 over the long term. You may vote once every thirty days.
